CTLA-4-Hemmer bei SCLC-Patienten

Demenz und Depression bei Patienten mit idiopathischem Parkinson-Syndrom

Hemmer 6/7

Although flow cytometric DNA ploidy has turned out as a significant predictor of survival in oral squamous cell carcinoma, little is known about the underlying karyotypic structure of gross aneuploidy. We therefore analysed one diploid and 9 aneuploid carcinomas with relative DNA contents between 1.1 and 2.8 by fluorescence in situ hybridization with topologic markers for the centromere (3cen) ...

Quantifizierung von Lungenarterienvolumina und perivaskulären Fibrosierungen bei Patienten mit fibrosierenden Lungengerüstveränderungen

Zusammenfassung. Prospektiv wurden je fünf Patienten mit cardiopulmonalem Normalbefund und Lungenfibrose mittels Thorax Spiral-Computertomographie (CT) und Rechtsherzkatheteruntersuchung zur Abklärung eines obstruktiven Schlafapnoesyndroms bzw. pulmonaler Hypertonie untersucht. In den SpiralCT-Volumendatensätzen wurden seitengetrennt die Lungen segmentiert. Anschließend wurde der pulmonalarteri...

Augmentation of CTLA-4 expression by wortmannin: involvement of lysosomal sorting properties of CTLA-4.

CTLA-4 (CD152) is transiently induced on the cell surface of activated T cells and expression is limited at a low level. In this study, we investigated the possibility that phosphatidylinositol 3 kinase (PI 3-K) and other related PI kinases associated with the cytoplasmic domain of CTLA-4 are involved in intracellular trafficking and sorting of CTLA-4 protein. Treatment with micromolar concentr...

CTLA-4: From conflict to clinic

CTLA-4 was first identified in 1991 as a second receptor for the T cell costimulation ligand B7. Uncertainties about its biological function plagued the early years after its discovery until 1995, when it was confirmed to be an inhibitor of T cell responses. CTLA-4 has since scored in the clinic as a target for antitumor therapy and as a soluble inhibitor of autoimmunity.